Patients achieve a high 2-year survival and deep MRD-negative remissions with CAR T-cell therapy followed by stem cell transplant in B-cell ALL.
Jax DiEugenio
Advertisement
Articles by Jax DiEugenio
Raludotatug deruxtecan (R-DXd) earned FDA breakthrough designation for CDH6-expressing platinum-resistant ovarian cancers after bevacizumab (Avastin; Genentech) treatment.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Integrated Care for Chronic Conditions: A Randomized Care Management Trial
2
It’s Time to Reimagine Reimbursement for CAR T-Cell Therapy
3
What ACA Subsidy Expiration Means for Coverage Costs, Employer Strategy, and ICHRAs: Q&A With Ben Light
4
Daratumumab Offers Hope for Delaying Progression to Active MM: Peter Voorhees, MD
5
